Does Glyxambi Cause Weight Loss?
Yes, Glyxambi (empagliflozin/linagliptin) causes modest weight loss, primarily driven by its empagliflozin component, with reductions of approximately 2-3.5% of body weight (2-3 kg) over 24-52 weeks.
Understanding the Weight Loss Mechanism
The weight loss effect of Glyxambi comes almost entirely from empagliflozin, the SGLT-2 inhibitor component. Empagliflozin promotes urinary glucose excretion (glucosuria), leading to caloric loss of approximately 200-300 calories per day 1. The linagliptin component (a DPP-4 inhibitor) is weight-neutral and does not contribute to weight reduction [@1,@2].
Clinical Trial Evidence
Direct Glyxambi Studies
In the pivotal FDA registration trial of 686 patients with type 2 diabetes on metformin, Glyxambi demonstrated statistically significant weight loss compared to linagliptin alone [@13,3]:
- Glyxambi 10 mg/5 mg: -3.1% body weight change (approximately 2.7 kg loss from baseline of 87 kg)
- Glyxambi 25 mg/5 mg: -3.4% body weight change (approximately 3.0 kg loss from baseline of 85 kg)
- Linagliptin 5 mg alone: -0.7% body weight change
- Empagliflozin alone: -3.0% to -3.5% body weight change
The weight loss with Glyxambi was statistically significant versus linagliptin (p<0.0001) but showed no significant difference compared to empagliflozin alone, confirming that empagliflozin drives the weight effect [@13,3].
Meta-Analysis Confirmation
A 2020 meta-analysis of 6 randomized controlled trials (2,857 patients) confirmed that empagliflozin/linagliptin combination produced significantly greater weight reduction compared to linagliptin monotherapy, but the effect was equivalent to empagliflozin alone 4.
Weight Loss Magnitude in Context
According to Endocrine Society guidelines, SGLT-2 inhibitors as a class produce a mean body weight reduction of -2.37% (95% CI: -2.73 to -2.02) compared to placebo [@2]. This positions Glyxambi's weight effect as:
- More effective than: DPP-4 inhibitors alone (weight neutral), sulfonylureas (+1.8 to +3.0 kg), insulin (+0.6 to +10 kg), thiazolidinediones (+3.0 kg) [@1,2]
- Less effective than: GLP-1 receptor agonists (-0.6 to -3.0 kg depending on agent) [@1,2]
- Similar to: Other SGLT-2 inhibitors (canagliflozin -2.61%, dapagliflozin -2.06%) [@2]
Time Course and Durability
Weight loss with Glyxambi follows a predictable pattern:
- Maximal effect: Achieved by 24 weeks
- Durability: Weight loss is maintained through 52 weeks without regain after the initial reduction [@2,@3,5]
- No plateau effect: Some evidence suggests continued gradual weight reduction beyond 3 months 6
Factors Affecting Weight Loss Response
Gender Differences
Male patients experience greater weight loss than females with empagliflozin (-3.59 kg vs -2.30 kg, p=0.029) 6.
Renal Function Impact
Patients with GFR >90 mL/min show greater weight loss than those with GFR <90 (-3.34 kg vs -2.16 kg) 6. This is expected since empagliflozin's mechanism depends on adequate renal filtration of glucose.
Baseline BMI
Weight loss appears consistent across BMI categories (BMI <25-30-35, >35), suggesting the effect is not limited to specific obesity classes 6.
Important Clinical Caveats
Compensatory Metabolic Adaptations
The observed weight loss is less than predicted based on caloric loss alone 7. Animal studies suggest compensatory mechanisms including:
- Decreased FGF21 levels
- Reduced deiodinase 2 (Dio2) expression in adipose tissue
- Metabolic adaptations that partially offset caloric losses
This explains why patients don't lose the 10-15 kg that would be expected from continuous 200-300 calorie daily deficits.
Not Primarily a Weight Loss Medication
While Glyxambi causes weight loss, it should not be prescribed solely for weight management. The primary indication is glycemic control in type 2 diabetes. For patients requiring substantial weight loss (BMI >35 with diabetes), GLP-1 receptor agonists are more effective and should be prioritized 8.
Practical Prescribing Considerations
When to emphasize Glyxambi's weight benefit:
- Patients with type 2 diabetes requiring glucose control who are overweight/obese
- Patients who have gained weight on insulin, sulfonylureas, or thiazolidinediones
- Patients with cardiovascular disease or heart failure where empagliflozin provides additional mortality benefit 1
- Patients who cannot tolerate or afford GLP-1 receptor agonists
Set realistic expectations:
- Inform patients to expect 2-3 kg (4-7 lb) weight loss over 6 months
- Weight loss is a beneficial side effect, not the primary therapeutic goal
- Combining with lifestyle modifications enhances results
- The medication does not cause hypoglycemia, facilitating safe exercise programs [@2]
Monitor for:
- Genital mycotic infections (more common with SGLT-2 inhibitors)
- Volume depletion in elderly or those on diuretics
- Reduced efficacy in patients with eGFR <45 mL/min
[@1,@2,@3,@6,@13,@14,@16,6]